The ultra‑long‑acting multispecific antibody platform integrates AI‑assisted VHH discovery, developability optimization, and mismatch‑free assembly to achieve long‑acting multispecific antibodies at high concentrations. This enables subcutaneous dosing every ≥3 months, delivering synergistic or complementary multi‑target effects and significantly improving patient compliance.
